ドライアイの市場規模、シェア、成長分析：製品タイプ別、製剤タイプ別、流通チャネル別、地域別 - 産業予測 2025～2032年

ドライアイの市場規模は2023年に56億米ドルと評価され、2024年の60億5,000万米ドルから2032年には112億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.1％で成長する見通しです。

世界のドライアイ（DED）市場は、高齢者、特に女性の間で有病率が増加していることが成長の原動力となっています。瘢痕性角膜炎や機能不全性流涙症候群のような症状は、高齢化人口のかなりの部分を占めるこの眼表面疾患の重要性を強調しています。世界保健機関（WHO）は、60歳以上の高齢者が2015年から2050年の間に12％から22％へとほぼ倍増すると予測しており、この人口層の80％が低・中所得国に居住していることから、効果的なドライアイ治療に対する需要が高まることが予想されます。この急成長市場で薬剤の普及を促進するには、臨床試験と調査の強化が不可欠であり、特に高齢者人口が眼障害に対してより脆弱になっているためです。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

ドライアイ市場規模：製品タイプ別：& CAGR（2025-2032）

• 市場概要
• シクロスポリン
• コルチコステロイド
• リフィテグラスト
• 眼用潤滑剤
• 涙点プラグ
• その他

ドライアイ市場規模：製剤タイプ別：& CAGR（2025-2032）

• 市場概要
• 液体
• ゲル
• 軟膏
• その他

ドライアイ市場規模：流通チャネル別：& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• スーパーマーケット/ハイパーマーケット
• その他の店舗
• オンライン薬局

ドライアイ市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Novartis（Switzerland）
• Allergan（Ireland）
• AbbVie（US）
• Johnson & Johnson（US）
• Bausch+Lomb（Canada）
• Rohto Pharmaceutical Co., Ltd.（Japan）
• Oculis（Switzerland）
• Visus Therapeutics（US）
• Kala Pharmaceuticals（US）
• Sun Pharmaceutical Industries Ltd.（India）
• Prestige Consumer Healthcare（US）
• Similasan Corporation（Switzerland）
• Scope Ophthalmics（UK）
• Thea Pharmaceuticals（France）
• Ursapharm Arzneimittel GmbH（Germany）
• EyeGate Pharmaceuticals, Inc.（US）
• Aldeyra Therapeutics（US）
• QuidelOrtho Corporation（US）

結論と推奨事項

Dry Eye Disease Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.05 billion in 2024 to USD 11.29 billion by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global dry eye disease (DED) market is poised for growth, driven by an increasing prevalence of the condition among older adults, particularly women. Conditions like keratitis sicca and dysfunctional tear syndrome underline the significance of this ocular surface disease, which affects a substantial segment of the aging population. With the World Health Organization projecting that individuals aged 60 and above will nearly double from 12% to 22% between 2015 and 2050, and with a striking 80% of this demographic residing in low- and middle-income countries, the demand for effective dry eye treatments is set to rise. Enhanced clinical trials and research are essential to boost drug penetration in this burgeoning market, particularly as the elderly population becomes more vulnerable to eye disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Dry Eye Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Dry Eye Disease Market Segments Analysis

Global Dry Eye Disease Market is segmented by Product Type, Formulation Type, Distribution Channel: and region. Based on Product Type, the market is segmented into Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Others. Based on Formulation Type, the market is segmented into Liquid, Gel, Ointment and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Supermarket/Hypermarket, Other Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Dry Eye Disease Market

The dry eye disease market, encompassing conditions like keratoconjunctivitis sicca (KCS), serves an extensive population, with around 360 million affected globally. This prevalent ocular disorder manifests through symptoms of dryness, irritation, redness, fatigue, and blurred vision. The incidence is not limited to age, as it is increasingly observed in both younger and older demographics, largely attributed to heightened screen exposure, poor dietary habits, growing contact lens usage, and more frequent LASIK surgeries. As individuals age, the lachrymal glands' tear production diminishes, leading to dry eye complaints. Hence, the escalating prevalence of dry eye disease, particularly among aging populations, significantly propels the demand for dry eye treatments in the market.

Restraints in the Dry Eye Disease Market

The Dry Eye Disease market faces significant restraints due to a lack of public awareness regarding eye health. Many individuals do not recognize the importance of seeking treatment for common dry eye symptoms, which are often misconstrued and can be effectively managed with accurate diagnosis and appropriate medications. Typically, patients only consult ophthalmologists when experiencing severe discomfort, leading to the underdiagnosis of symptoms like redness and burning. This lack of recognition limits the pool of individuals who could benefit from prescription treatments. A UK survey revealed that one in four adults neglects biannual eye examinations as recommended, indicating a pervasive ignorance around eye health, particularly among children.

Market Trends of the Dry Eye Disease Market

The dry eye disease market is experiencing a notable upward trend characterized by heightened investment in research and development, culminating in successful clinical trials and a surge in new product approvals. Pharmaceutical companies like Aldeyra Therapeutics, Inc. are leading the charge with promising candidates like Reproxalap, currently in Phase III trials, setting a precedent for innovation. This influx of clinical activity not only fosters competitive differentiation but also enhances the treatment landscape, thereby significantly boosting revenue potential. Such strategic initiatives reflect a commitment to addressing unmet needs and solidifying market presence, positioning the dry eye disease market for robust growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Dry Eye Disease Market Size by Product Type: & CAGR (2025-2032)

• Market Overview
• Cyclosporine
• Corticosteroids
• Lifitegrast
• Ocular Lubricant
• Punctal Plugs
• Others

Global Dry Eye Disease Market Size by Formulation Type: & CAGR (2025-2032)

• Market Overview
• Liquid
• Gel
• Ointment
• Others

Global Dry Eye Disease Market Size by Distribution Channel: & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Supermarket/Hypermarket
• Other Stores
• Online Pharmacies

Global Dry Eye Disease Market Size & CAGR (2025-2032)

• North America (Product Type:, Formulation Type:, Distribution Channel:)
  • US
  • Canada
• Europe (Product Type:, Formulation Type:, Distribution Channel:)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type:, Formulation Type:, Distribution Channel:)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type:, Formulation Type:, Distribution Channel:)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type:, Formulation Type:, Distribution Channel:)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rohto Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oculis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Visus Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kala Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prestige Consumer Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Similasan Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Scope Ophthalmics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thea Pharmaceuticals (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ursapharm Arzneimittel GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyeGate Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aldeyra Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuidelOrtho Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations